Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Mateos, MV; Nahi, H; Legiec, W; Grosicki, S; Vorobyev, V; Spicka, I; Hungria, V; Korenkova, S; Bahlis, N; Flogegard, M; Blade, J; Moreau, P; Kaiser, M; Iida, S; Laubach, J; Magen, H; Cavo, M; Hulin, C; White, D; De Stefano, V; Clemens, PL; Masterson, T; Lantz, K; O'Rourke, L; Heuck, C; Qin, X; Parasrampuria, DA; Yuan, ZL; Xu, S; Qi, M; Usmani, SZ

Usmani, SZ (corresponding author), Atrium Hlth, Levine Canc Inst, Charlotte, NC 28204 USA.

LANCET HAEMATOLOGY, 2020; 7 (5): E370

Abstract

Background Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengthy infusion that affects quality of life, and infus......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索